This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
ANI Pharmaceuticals (ANIP) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
ANI (ANIP) delivered earnings and revenue surprises of 3.08% and 1.73%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate ANI Pharmaceuticals (ANIP) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
ANI (ANIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for May 24th
by Zacks Equity Research
ANIP, BHVN, FVRR, KBAL, and PLNT have been added to the Zacks Rank #5 (Strong Sell) List on May 24, 2021
ANI Pharmaceuticals (ANIP) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
ANI (ANIP) delivered earnings and revenue surprises of 42.47% and 13.59%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: ANI Pharmaceuticals (ANIP) Q1 Earnings Expected to Decline
by Zacks Equity Research
ANI (ANIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ANI Pharmaceuticals (ANIP) Enters Overbought Territory
by Zacks Equity Research
ANI Pharmaceuticals (ANIP) has moved higher as of late, but there could definitely be trouble on the horizon for this company
ANI Pharmaceuticals (ANIP) Q4 Earnings Miss Estimates
by Zacks Equity Research
ANI (ANIP) delivered earnings and revenue surprises of -20.00% and 3.91%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: ANI Pharmaceuticals (ANIP) Q4 Earnings Expected to Decline
by Zacks Equity Research
ANI (ANIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should Value Investors Pick ANI Pharmaceuticals (ANIP) Now?
by Zacks Equity Research
Let's see if ANI Pharmaceuticals (ANIP) stock is a good choice for value-oriented investors right now from multiple angles.
Analysts Estimate ANI Pharmaceuticals (ANIP) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
ANI (ANIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ANI Pharmaceuticals (ANIP) Q2 Earnings Miss Estimates
by Zacks Equity Research
ANI (ANIP) delivered earnings and revenue surprises of -2.82% and 6.06%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: ANI Pharmaceuticals (ANIP) Q2 Earnings Expected to Decline
by Zacks Equity Research
ANI (ANIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for July 8th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
ANI Pharmaceuticals (ANIP) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
ANI (ANIP) delivered earnings and revenue surprises of 16.85% and 0.76%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Are Investors Undervaluing ANI Pharmaceuticals (ANIP) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
AMAG Sees High Feraheme Sales, To Sell Women Healthcare Drugs
by Zacks Equity Research
AMAG (AMAG) plans to divest two of its women healthcare drugs, Intrarosa and Vyleesi. Its marketed drug, Feraheme, achieves record sales in 2019.
New Strong Sell Stocks for March 5th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
ANI Pharmaceuticals (ANIP) Q4 Earnings and Revenues Lag Estimates
by Zacks Equity Research
ANI (ANIP) delivered earnings and revenue surprises of -8.47% and -6.32%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
4 Drug/Biotech Outperformers That May Lose Steam in 2020
by Kinjel Shah
Here we discuss some biotech stocks, which are up this year so far but might not be good additions to your portfolio.
New Strong Sell Stocks for December 4th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
Moving Average Crossover Alert: ANI Pharmaceuticals
by Zacks Equity Research
ANI Pharmaceuticals could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.
ANI Pharmaceuticals (ANIP) Lags Q3 Earnings and Revenue Estimates
by Zacks Equity Research
ANI (ANIP) delivered earnings and revenue surprises of -16.89% and -10.25%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
ANI Pharmaceuticals (ANIP) to Report Q3 Results: Wall Street Expects Earnings Growth
by Zacks Equity Research
ANI (ANIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks.com featured highlights include: Assurant, Opera, ANI, eXp and Avista
by Zacks Equity Research
Zacks.com featured highlights include: Assurant, Opera, ANI, eXp and Avista
Zacks.com featured highlights include: Assurant, Opera, ANI, eXp and Avista
by Zacks Equity Research
Zacks.com featured highlights include: Assurant, Opera, ANI, eXp and Avista